AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
MONDAY, April 8, 2024 -- For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Pharmaceuticals | Study